This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) advanced 1.15% to $446.83 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&amp;P 500 Index falling 2.64% to 7,383.74 and Dow Jones Industrial Average falling 1.35% to 50,866.78.
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals Inc. closed 12.03% short of its 52-week high of $507.92, which the company achieved on March 10th.
The stock outperformed some of its competitors Friday, as AbbVie Inc. (ABBV) rose 1.02% to $227.23, Krystal Biotech Inc. (KRYS) fell 2.21% to $301.00, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 9.20% to $7.30.
Trading volume (1.5 M) eclipsed its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled June 5, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-05-26 1637ET

VRTX

Vertex Pharmaceuticals (VRTX) stock rose 1.15% to $446.83, outperforming the broader market and competitors on a poor trading day. The S&P 500 fell 2.64%, while peers like AbbVie gained slightly and Krystal Biotech dropped. VRTX marked its third consecutive gain, closing 12.03% below its 52-week high of $507.92. Trading volume reached 1.5 million shares, exceeding the 50-day average.

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day